8910 University Center Lane, Suite 400
San Diego, CA 92122

2 September 2026

Dear Shareholder

THE HYDRATION PHARMACEUTICALS COMPANY LIMITED – UPCOMING EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

The Hydration Pharmaceuticals Company Limited (ACN 620 385 677) (**ASX:HPC**) (**Hydralyte USA** or the **Company**) advises that the Company will hold an extraordinary general meeting of its shareholders (**Shareholders**) at 10:00am (AEST) on Thursday, 8 October 2026 (the **Meeting**).

This meeting will be held as a virtual meeting. Shareholders may attend online via the online meeting platform provided by the Company's share registry.

The Company is not required to send hard copies of the Notice of Meeting (**Notice**) to Shareholders. The Notice is available under the 'ASX Announcements' section on the Company's website at https://hydralyte.com/pages/investors or under the Announcements section on the Company's ASX platform at https://www2.asx.com.au/markets/trade-our-cash-market/announcements.hpc

The Company strongly encourages all Shareholders to vote by proxy prior to the Meeting. Proxy forms for the Meeting must be lodged before 10:00am (AEST) on Tuesday, 8 October 2026. A copy of your personalised voting form is enclosed for convenience, or alternatively, you can submit your votes online via https://portal.automic.com.au/investor/home and follow the instructions on your Voting Form.

Shareholders who wish to attend and participate in the Meeting can do so via the online meeting platform, where Shareholders will be able to watch, listen, ask questions and vote online. Details on how to access the virtual Meeting are provided in the Notice. Shareholders can also submit, and are encouraged to submit, any questions in advance of the Meeting by emailing questions to hydralytecosec@cdplus.com.au by no later than 10:00am (AEST) on Thursday, 1 October 2026.

The Notice and the accompanying Explanatory Memorandum should be read in its entirety. The Explanatory Memorandum contains important information about the matters to be considered at the Meeting to assist Shareholders to determine how to vote on the resolutions set out in the Notice.

Should you wish to discuss any of the matters detailed in this letter, the Notice or the Explanatory Memorandum, please contact the Company Secretary on +61 3 9614 2444 or hydralytecosec@cdplus.com.au.

Yours faithfully

Nick Berry
Non-Executive Chair
The Hydration Pharmaceuticals Company Limited